Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 1
2000 2
2002 1
2003 1
2006 1
2007 1
2011 1
2012 1
2017 1
2020 3
2021 1
2022 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Benjamin R, et al. Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5. Lancet. 2020. PMID: 33308471 Free PMC article. Clinical Trial.
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. Benjamin R, et al. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. Lancet Haematol. 2022. PMID: 36228643 Free PMC article. Clinical Trial.
Regulation of peroxisomal trafficking and distribution.
Covill-Cooke C, Toncheva VS, Kittler JT. Covill-Cooke C, et al. Among authors: toncheva vs. Cell Mol Life Sci. 2021 Mar;78(5):1929-1941. doi: 10.1007/s00018-020-03687-5. Epub 2020 Nov 3. Cell Mol Life Sci. 2021. PMID: 33141311 Free PMC article. Review.
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract.
DeFilipp Z, Damania AV, Kim HT, Chang CC, El-Jawahri A, McAfee SL, Bottoms AS, Toncheva V, Smith MM, Dolaher M, Perry L, White M, Diana B, Connolly S, Dey BR, Frigault MJ, Newcomb RA, O'Donnell PV, Spitzer TR, Mansour MK, Weber D, Ajami NJ, Hohmann E, Jenq RR, Chen YB. DeFilipp Z, et al. Among authors: toncheva v. Blood Adv. 2024 May 14;8(9):2074-2084. doi: 10.1182/bloodadvances.2024012556. Blood Adv. 2024. PMID: 38471063 Free PMC article. Clinical Trial.
Poly-L-glutamic acid derivatives as vectors for gene therapy.
Dekie L, Toncheva V, Dubruel P, Schacht EH, Barrett L, Seymour LW. Dekie L, et al. Among authors: toncheva v. J Control Release. 2000 Mar 1;65(1-2):187-202. doi: 10.1016/s0168-3659(99)00235-7. J Control Release. 2000. PMID: 10699280
17 results